Desmoid Tumor (Aggressive Fibromatosis)

Desmoid tumors, also termed aggressive fibromatosis, are rare benign fibroblastic neoplasms characterized by monoclonal proliferation of myofibroblasts with locally infiltrative growth. Despite lacking metastatic potential, these tumors pose significant clinical challenges due to their unpredictable natural history, local aggressiveness, and high recurrence rates following surgical resection.

The paradigm for desmoid management has shifted dramatically over the past decade. Historical aggressive surgical approaches have been replaced by surveillance-first strategies, recognizing that approximately 50% of desmoids remain stable or spontaneously regress without intervention. This evolution reflects growing understanding of desmoid biology and the recognition that treatment-related morbidity may exceed disease-related morbidity in many patients.

Wnt-Beta-Catenin Pathway

Desmoid tumorigenesis is driven by aberrant activation of the Wnt-beta-catenin signaling pathway through two distinct genetic mechanisms.

Risk Factors

View larger

View larger

Macroscopic Features

Desmoid tumors present as firm, poorly circumscribed masses:

• Consistency: Firm to rubbery, resembling scar tissue or keloid
• Margins: Infiltrative, no true capsule, irregular borders
• Cut surface: Whorled, glistening white-grey appearance (collagenous)
• Size: Variable, typically 5-15cm at diagnosis (can be larger)
• Fascial involvement: Common, tumor follows fascial planes
• Muscle infiltration: Invades between muscle fibers

Microscopic Features

Immunohistochemistry

Diagnostic markers:

Prognostic Factors

Long-Term Surveillance

Algorithm

View larger

Active Surveillance (First-Line)

Paradigm shift rationale:

The evolution from aggressive surgery to surveillance-first reflects recognition of desmoid natural history:

• 50% of desmoids remain stable or regress without intervention
• Surgery has high morbidity (functional loss, recurrence 20-40%)
• Treatment complications may exceed disease-related morbidity
• Benign nature (no metastasis) allows time for observation
• Progression after period of stability is manageable

Indications for active surveillance:

Surveillance protocol:

Triggers for intervention:

Intervention considered if:

• Progressive growth on serial MRI (greater than 20% volume increase)
• Increasing symptoms (pain, functional impairment)
• Development of complications (nerve compression, vascular compromise)
• Bowel or ureteric obstruction (intra-abdominal)
• Patient anxiety despite stable disease (shared decision-making)

Patient counseling:

Key discussion points:

• Benign tumor, never spreads to other organs
• 50% chance tumor stays same or shrinks without treatment
• Surgery has risks: recurrence 20-40%, functional loss
• Monitoring is safe, active approach
• Can intervene anytime if tumor progresses
• Long-term commitment to surveillance required

Indications

Systemic therapy reserved for:

• Unresectable tumors with documented progression
• Recurrent tumors not amenable to further surgery
• Symptomatic intra-abdominal desmoids
• Multifocal FAP-associated desmoids
• Patient preference to avoid surgery

First-Line Systemic Options

Role and Indications

Radiotherapy is rarely used in modern desmoid management.

Indications for Surgery

Surgery is now reserved for selected cases after failure of surveillance:

Surgical Principles (Function Over Margins)

Critical paradigm difference from sarcoma:

Unlike sarcoma surgery where wide margins are mandatory:

• Positive margins acceptable to preserve function
• No survival impact of margin status (benign tumor)
• Recurrence manageable with surveillance or systemic therapy
• Function preservation is priority

Outcomes After Surgery

Disease-Related Complications

Treatment-Related Complications

Global Epidemiology

Desmoid-type fibromatosis is a rare tumour. Population-based and registry data give an estimated incidence of roughly 3 to 5 cases per million per year, with a female predominance and a peak in the third and fourth decades. According to PubMed, the prospective Dutch GRAFITI cohort and large referral-centre series confirm that the majority of patients managed with active surveillance never require active treatment, and that genotype (S45F CTNNB1) and tumour size predict the need for intervention (Schut et al., Ann Surg 2022; DOI). The defining molecular feature, CTNNB1 mutation in approximately 85% of sporadic cases, is consistent across international cohorts (Gronchi et al., Ann Oncol 2014; DOI).

Side-by-Side Guideline Guidance

Registry & Prospective Evidence

Practice Variation & Global Access

International practice has converged on a surveillance-first, multidisciplinary model coordinated through specialist sarcoma centres, though access to newer agents varies by jurisdiction. Suspected desmoid tumours should be discussed with a specialist sarcoma multidisciplinary team, with image-guided core needle biopsy arranged locally or at the referral centre. Tamoxifen is widely available and inexpensive, and nuclear beta-catenin immunohistochemistry is available through standard anatomical pathology services. Sorafenib and nirogacestat regulatory and reimbursement status differs between countries, so confirm local availability before counselling patients on systemic options.